FAQ on CNS Pharmaceuticals Inc. Q2 2025 Results and TPI 287 Phase 2 GBM Trial Advancements

What were CNS Pharmaceuticals Inc.’s Q2 2025 financial results?

CNS Pharmaceuticals Inc. reported a Q2 2025 net loss of $2.4 million, slightly improved from $2.5 million in Q2 2024, with R&D expenses rising to $1.2 million and G&A expenses falling to $1.2 million. The company ended the quarter with $12.1 million in cash.

What is TPI 287 and its significance?

TPI 287 is an abeotaxane drug candidate by CNS Pharmaceuticals that stabilizes microtubules, inhibits cell division, and has shown potential to cross the blood-brain barrier to treat CNS tumors, with promising Phase 1 results and an excellent safety profile.

When is CNS Pharmaceuticals planning to begin the Phase 2 study of TPI 287 for GBM?

CEO John Climaco stated that CNS Pharmaceuticals is on track to begin a Phase 2 study of TPI 287 for glioblastoma multiforme (GBM) in the first half of 2026.

What are the indications for which TPI 287 has received Orphan Drug Designation?

TPI 287 has received Orphan Drug Designation for multiple CNS indications, though the specific indications are not detailed in the provided content.

How has TPI 287 been tested so far?

TPI 287 has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for various diseases, including recurrent glioblastoma, advanced malignancies, and breast cancer metastatic to the brain.

What is the financial runway for CNS Pharmaceuticals Inc.?

CNS Pharmaceuticals Inc. ended Q2 2025 with $12.1 million in cash, which is sufficient to fund operations into the second half of 2026.

Where can I find more information about CNS Pharmaceuticals Inc.?

More information about CNS Pharmaceuticals Inc. is available in the company’s newsroom at https://ibn.fm/CNSP.

What is TinyGems and its relation to CNS Pharmaceuticals Inc.?

TinyGems is a specialized communications platform focusing on innovative small-cap and mid-cap companies, part of the Dynamic Brand Portfolio @ IBN, which provides various services including press release enhancement and social media distribution for companies like CNS Pharmaceuticals Inc.